Ongoing study - The results of studies on the efficacy and safety of medicines can only be fully generalised if all relevant populations are adequately represented. However, women have historically been underrepresented in clinical research and, despite some progress, this underrepresentation persists in certain areas. This may limit the generalisability of the findings and lead to an incomplete assessment of the benefits or adverse effects of medicines, knowing that sex-related differences have been described regarding pharmacokinetics, efficacy and tolerability.
The aim of this study is to synthesise the findings from systematic reviews of the literature concerning sex-related differences in the efficacy and safety of medicines. The study will help map out the areas in which the evidence is robust, insufficient or contradictory, and identify priorities for improving the design, analysis and reporting of clinical research.
- Study 2018-15 (HSR) Shifting care from inpatient towards day-care and ambulatory care: impact on readmission rates & post-discharge mortality
- Study 2020-01 (HTA) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty
- Study 2023-06 (HSR) How to improve the access to supportive care for children with life-threatening or life-limiting diseases and their family?
- Study 2023-53 (HSR) Evaluation of the pilot project to implement the New Deal model.
- Study 2023-60 (collaboration): Clinical effectiveness and safety of immunisation against respiratory syncytial virus (RSV)
